GlassScriptPhysician profile
Larissa M Allen
NPI 1659536480
$6,984.53
in general payments reported to CMS, 2019-2025
33 companies · $635 in 2025
The $635 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $797 · 2021: $1,286 · 2022: $1,333 · 2023: $1,194 · 2024: $1,093 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,900 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,900.27 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,515.60 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Celgene Corporation | $749.31 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $456.69 | 2019-2024 | Eohilia |
| Janssen Biotech, INC. | $354.71 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $325.41 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Intercept Pharmaceuticals, INC. | $324.38 | 2019-2024 | Ocaliva |
| Pfizer INC. | $321.34 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $226.06 | 2021-2023 | |
| Genzyme Corporation | $162.03 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $129.97 | 2020-2023 | Rebyota |
| Ardelyx, INC. | $126.94 | 2022-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Gilead Sciences, INC. | $119.35 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $119.25 | 2023-2024 | Dupixent |
| Qol Medical, LLC | $113.03 | 2019-2025 | Sucraid, Sucraid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $112.38 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $78.12 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $75.64 | 2021-2022 | |
| Redhill Biopharma INC. | $70.24 | 2021-2023 | |
| Madrigal Pharmaceuticals | $68.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $60.23 | 2020-2023 | Linzess |
| Medtronic, INC. | $48.43 | 2021-2022 | |
| Abbott Laboratories | $48.12 | 2023 | Mitraclip |
| Celltrion USA INC. | $45.40 | 2024 | Zymfentra |
| Alfasigma USA, INC. | $43.60 | 2020 | |
| Braintree Laboratories, INC. | $38.93 | 2019-2022 | |
| Biocon Biologics INC | $23.04 | 2024 | Hulio |
| Medtronic USA, INC. | $22.84 | 2019 | |
| Allergan, INC. | $22.73 | 2019 | |
| Evoke Pharma, INC. | $15.23 | 2024 | |
| Lilly USA, LLC | $15.00 | 2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $14.18 | 2022 | |
| Capsovision, INC. | $13.15 | 2023 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larissa Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.